A newly described stage of a lymph node-like structure seen in liver tumours after presurgical immunotherapy may be vital to successfully treating patients with hepatocellular carcinoma, according to a study by researchers from the Johns Hopkins Kimmel Cancer Center .

The study, published in Nature Immunology , provides new information about lymph node-like structures called tertiary lymphoid structures.

These structures, which are highly organised collections of immune B and T cells, are found in some patients treated with immune checkpoint inhibitors — substances that reactivate the body's natural anti-cancer immunity — and are associated with greater treatment response.

However, researchers are still trying to fully understand what these structures contribute to immune responses to cancer, how they change over time, and what finding them in tumours means for patients.

The study identifies a previously unknown form of these structures.

Patients who have more of these structures are less likely to have a recurrence of their cancer after surgery, the investigators found.

“We identified the life cycle of tertiary lymphoid structures in patients with liver cancer, and the takeaway is that these structures may be very important in the generation of anti-tumour immunity and may increase the likelihood of curing the cancer,” says anti-tumour immunity and may increase the likelihood of curing the cancer,” says Mark Yarchoan, MD , an associate professor of oncology at the Johns Hopkins Kimmel Cancer Center Center.

Yarchoan and his colleagues previously conducted the first clinical trials of immunotherapy before surgery for hepatocellular carcinoma.

Only some of the patients were cured with this approach, and the investigators have been trying to understand why.

“One of the things that struck us when we looked at these tumours was that patients who were responding to immunotherapy had tertiary lymphoid structures,” he says.

Like lymph nodes, the structures have infection-fighting immune B cells in the middle and tumour-killing immune T cells on the outside.

“We wanted to learn what these structures are doing.”

They found that tumours with more tertiary lymphoid structures after immunotherapy shrunk more and were less likely to reoccur after surgical removal.

Tumours without these structures, by contrast, didn't shrink and were more likely to come back after surgery.

Tertiary lymphoid structures that grew in the center of tumours rather than around the edges were particularly beneficial.

When the investigators looked at biopsies taken before and after immunotherapy, they found that patients who developed these structures had what looked like precursors of tertiary lymphoid structures prior to beginning therapy.

When the study's lead author, Daniel Shu, MD, then a medical oncology fellow at Johns Hopkins, examined sites where the patients' tumours had been eliminated, he discovered a transformation in the tertiary lymphoid structures remaining at the site.

“In tumours where immunotherapy had the greatest effect, we found another form of tertiary lymphoid structure that has not been seen before. In this form, there was dispersion of B cells and apparent retention of so-called T cell zones, where T cells are primed to identify antigens,” says Shu, now at the University of Maryland School of Medicine.

“These same patients tend to have the greatest benefit from immunotherapy given in this way. While a lot more work needs to be done, our hypothesis is that this form is a late stage of tertiary lymphoid structure that may contribute to the long-term benefit we are seeing in these patients.”

The next step for the team is to determine if they can induce the formation of tertiary lymphoid structures in patients who don't develop them on their own after starting immunotherapy.

They also plan to look at how different combinations of immunotherapies or other presurgical therapies affect tertiary lymphoid structure formation and patient outcomes.

The discovery may also have implications for other types of cancer, since the new form of tertiary lymphoid structure reported here was also seen by the authors in two other types of tumors known to respond to immunotherapy.

The study was a collaborative effort of the imCORE imCORENetwork, and a co-leader of the study was Elana Fertig, Ph.D. , a professor of oncology and biomedical engineering; division director of oncology quantitative sciences; and co-director of the Convergence Institute at Johns Hopkins. 

Source: Johns Hopkins Medicine